Panzer S
Clinical Department for Blood Group Serology, University of Vienna, Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Vox Sang. 2001 Jan;80(1):72-8. doi: 10.1046/j.1423-0410.2001.00002.x.
The aims of the 10th International Platelet Serology and Genotyping Workshop were to evaluate the proficiency of platelet immunology determinations.
There were 40 participants from 25 countries of four continents. Thirty-eight institutions reported results for genotyping, and 38 institutions reported their serological results. For genotyping, EDTA-anticoagulated whole-blood samples were provided (to allow the inclusion of DNA-separation methodology in the analysis) as well as separated DNA of a and b alleles for human platelet antigen (HPA)-1 to -6. For serological evaluations, sera contained allo- and autoantibodies, and for sensitivity testing a standard freeze-dried sample of HPA-5 antibody.
All participants reported HPA-1, -2, -3 and -5 genotyping results; HPA-4 was determined in 29 laboratories and HPA-6 in 21. Results from 16 laboratories were concordant with the majority vote for all allotypes, eight institutions reported one deviation, five laboratories two, and nine laboratories three or more deviations. Twelve institutions had no deviation from the majority vote for HPA antibodies, nine had one, three had two, and 14 had three or more deviations. Most laboratories reported a reactivity of the standard anti-HPA-5b sample with HPA-5b platelets at a dilution of 1:4-1:8. Four laboratories detected anti-Gova in one sample. Seventeen laboratories reported no deviation from the majority vote for pan-reactive platelet antibodies, 12 had one deviation, two had two, and seven had three or more deviations. In addition, seven participants reported antibodies against glycoprotein IV (GPIV), three against glycoprotein V (GPV) and three against CD 109. These results were discussed at a meeting organized jointly with the International Society of Blood Transfusion (ISBT) 2000 Congress.
The results for pan-reactive antibodies were heterogeneous with most discrepancies from the majority vote. The provision of sufficient samples for many participants is difficult. Based on the results and discussion it is clear that frequent workshops are needed in the future. Therefore, workshops shall be organized regionally, and each region shall participate with one institution in international workshops. The latter are needed to assure international exchange of experience and quality.
第十届国际血小板血清学与基因分型研讨会的目的是评估血小板免疫学检测的熟练度。
来自四大洲25个国家的40名参与者。38个机构报告了基因分型结果,38个机构报告了血清学结果。对于基因分型,提供了乙二胺四乙酸(EDTA)抗凝全血样本(以便在分析中纳入DNA分离方法)以及人类血小板抗原(HPA)-1至-6的a和b等位基因的分离DNA。对于血清学评估,血清中含有同种抗体和自身抗体,并且为了进行敏感性测试,提供了HPA-5抗体的标准冻干样本。
所有参与者均报告了HPA-1、-2、-3和-5的基因分型结果;29个实验室检测了HPA-4,21个实验室检测了HPA-6。16个实验室的所有同种异型结果与多数投票结果一致,8个机构报告有1项偏差,5个实验室报告有2项偏差,9个实验室报告有3项或更多偏差。12个机构的HPA抗体结果与多数投票结果无偏差,9个机构有1项偏差,3个机构有2项偏差,14个机构有3项或更多偏差。大多数实验室报告标准抗HPA-5b样本与HPA-5b血小板在1:4至1:8稀释度下有反应性。4个实验室在1个样本中检测到抗戈瓦(Gova)抗体。17个实验室报告其全反应性血小板抗体结果与多数投票结果无偏差,12个机构有1项偏差,2个机构有2项偏差,7个机构有3项或更多偏差。此外,7名参与者报告了抗糖蛋白IV(GPIV)抗体,3名报告了抗糖蛋白V(GPV)抗体,3名报告了抗CD 109抗体。这些结果在与国际输血协会(ISBT)2000年大会联合组织的一次会议上进行了讨论。
全反应性抗体的结果存在异质性,大多数与多数投票结果存在差异。为许多参与者提供足够的样本很困难。基于这些结果和讨论,显然未来需要频繁举办研讨会。因此,研讨会应在区域内组织,每个区域应由一个机构参与国际研讨会。后者对于确保国际经验交流和质量是必要的。